Based on its teratogenic properties in developed chick embryos, it is recommended that rolapitant should be taken only when a valid diagnosis has been established and only at the recommended dose, not at a larger dose or for an extended period of time. Drug usage in pregnant women should be conducted after necessary studies and approvals from regulatory agencies.
(Cureus, 2022 Aug 17;14(8):e28097, doi: 10.7759/cureus.28097)
- TRADE NAME: Varubi (Tesaro)
- INDICATIONS: Delayed nausea and vomiting from chemotherapy, in combination with dexamethasone and a 5HT3-receptor antagonist
- CLASS: Antiemetic, Neurokinin 1 receptor antagonist
- HALF-LIFE: ~7 days
- FDA APPROVAL DATE: 09/01/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Thioridazine - PREGNANCY: A teratogen in animal studies. Drug usage in pregnant women should be conducted only after necessary studies and approvals from regulatory agencies.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of rolapitant in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/20/2025
